Nutritional Therapeutics
This article was originally published in The Tan Sheet
Executive Summary
Hauppauge, N.Y.-based manufacturer funding two clinical trials studying the effects of its Propax dietary supplement on chemotherapy-related, quality-of-life factors in cancer patients. NTI says Propax provides "premium nutritional support" with vitamins, minerals, amino acids, essential fatty acids, antioxidants and probiotics. Enrollment of 60 patients in a double-blind, placebo-controlled crossover study at Harbor-UCLA Medical Center is under way, and will run two-and-a-half months. An open label, non-crossover study following 40 patients over a 60-day period is slated to commence at the East Texas Medical Center Healthcare System this fall. The American Nutraceutical Association is coordinating the studies
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning